Clinical Policy: Leuprolide Acetate (Eligard, Lupaneta Pack, Lupron Depot, Lupron Depot-PED)
Reference Number: ERX.SPA.147
Effective date: 10.01.16
Last Review Date: 11.19
Line of Business: Commercial, Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Leuprolide acetate (Eligard®, Lupaneta Pack® [with norethindrone acetate tablets], Lupron Depot®, Lupron Depot-Ped®) is a gonadotropin-releasing hormone (GnRH) agonist.

FDA Approved Indication(s):
Leuprolide acetate is indicated for:
- Palliative treatment of advanced prostate cancer:
  - Leuprolide acetate injection
  - Eligard
  - Lupron Depot (7.5, 22.5, 30, 45)
- Management of endometriosis, including pain relief and reduction of endometriotic lesions:
  - Lupron Depot (3.75, 11.25)
  - Lupaneta Pack (3.75, 11.25)
  - Limitation(s) of use: Initial treatment course is limited to 6 months and use is not recommended longer than a total of 12 months due to concerns about adverse impact on bone mineral density.
- Preoperative hematologic improvement of patients with anemia caused by uterine leiomyomata (fibroids) administered concomitantly with iron therapy:
  - Lupron Depot (3.75, 11.25)
  - Limitation of use: the recommended treatment is limited to one injection (3 months)
- Treatment of children with central precocious puberty (CPP):
  - Lupron Depot-Ped (7.5, 11.25, 15, 30)

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

Health plan approved formularies should be reviewed for all coverage determinations. Requirements to use preferred alternative agents apply only when such requirements align with the health plan approved formulary.

It is the policy of health plans affiliated with Envolve Pharmacy Solutions™ that leuprolide acetate injection, Eligard, Lupaneta Pack, Lupron Depot, and Lupron Depot-Ped are medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Prostate Cancer (must meet all):
      1. Diagnosis of prostate cancer;
      2. Request is for leuprolide acetate injection (generic), Eligard, or Lupron Depot (7.5 mg, 22.5 mg, 30 mg, or 45 mg);
      3. Prescribed by or in consultation with an oncologist or urologist;
      4. Age ≥ 18 years;
      5. Request meets one of the following (a, b, or c):*
Leuprolide Acetate

**A.**
Leuprolide acetate injection (SC): Dose does not exceed 1 mg per day;
Eligard (SC)/Lupron Depot (IM): Dose does not exceed 7.5 mg per month, 22.5 mg per 3 months, 30 mg per 4 months, 45 mg per 6 months;
Dose is supported by practice guidelines or peer reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

*Prescribed regimen must be FDA-approved or recommended by NCCN*

**Approval duration:** 12 months

**B.**
**Endometriosis** (must meet all):
1. Diagnosis of endometriosis;
2. Request is for Lupron Depot/Lupaneta Pack (3.75 mg, 11.25 mg);
3. Prescribed by or in consultation with a gynecologist;
4. Age ≥ 18 years;
5. Endometriosis as a cause of pain is one of the following (a or b):
   a. Surgically confirmed;
   b. Clinically suspected and member has failed a 3-month trial of one of the following agents within the last year or has a documented intolerance or contraindication to the agent (i, ii, or iii):
      i. A non-steroidal anti-inflammatory drug;
      ii. An oral or depot injection contraceptive;
      iii. A progestin;
6. If request is for Lupaneta Pack, medical justification supports inability to use Lupron Depot (e.g., contraindications to the excipients);

*Prior authorization may be required for Lupron Depot*

7. Dose does not exceed 3.75 mg per month or 11.25 mg per 3 months.

**Approval duration:** 6 months

*Total duration of therapy should not exceed 12 months.*

**C.**
**Uterine Fibroids** (must meet all):
1. Diagnosis of anemia secondary to uterine leiomyomata (fibroids) confirmed by ultrasound;
2. Request is for Lupron Depot (3.75 mg, 11.25 mg);
3. Prescribed by or in consultation with a gynecologist;
4. Age ≥ 18 years;
5. Prescribed preoperatively to reduce fibroid size and improve hematologic control;
6. Dose does not exceed 3.75 mg per month or 11.25 mg per 3 months.

**Approval duration:** 3 months

*Total duration of therapy should not exceed 6 months.*

**D.**
**Central Precocious Puberty** (must meet all):
1. Diagnosis of CPP confirmed by all of the following (a, b, and c):
   a. Elevated basal luteinizing hormone (LH) level > 0.2 - 0.3 mIU/L (dependent on type of assay used) and/or elevated leuprolide-stimulated LH level > 3.3 - 5 IU/L (dependent on type of assay used);
   b. Difference between bone age and chronological age was > 1 year (bone age-chronological age);
   c. Age at onset of secondary sex characteristics is < 8 years if female, or < 9 years if male;
2. Request is for one of the following (a or b):
   a. Leuprolide acetate;
   b. Lupron Depot Ped: 7.5 mg, 11.25 mg, 15 mg, 30 mg;
3. Prescribed by or in consultation with a pediatric endocrinologist;
4. Member meets one of the following age requirements (a or b):
   a. Female: 2 - 11 years;
   b. Male: 2 - 12 years;
5. Dose does not exceed the following (a, b, or c):
   a. Diagnostic use: Leuprolide acetate (SC): 20 mcg/kg or as needed;
   b. Therapeutic use: Leuprolide acetate (SC): Initial: 50 mcg/kg per day; titrate dose upward by 10 mcg/kg per day if down-regulation is not achieved (higher mg/kg doses may be required in younger children);
   c. Therapeutic use: Lupron Depot-Ped (IM): 15 mg per month (1 month formulation) or 30 mg per 3 months (3 month formulation) (weight-based dosing).

Approval duration: 12 months

E. Breast and Ovarian Cancer (off-label) (must meet all):
1. Diagnosis of breast or ovarian cancer (including fallopian tube and primary peritoneal cancer);
2. Request is for one of the following (a or b):
   a. Breast cancer: Lupron Depot 3.75;
   b. Ovarian cancer: Lupron Depot 3.75 mg or 11.25 mg;
3. Prescribed by or in consultation with an oncologist;
4. Age ≥ 18 years;
5. Request meets one of the following (a, b, or c):*
   a. Breast or ovarian cancer: Dose does not exceed 3.75 mg per month;
   b. Ovarian cancer: Dose does not exceed 11.25 mg per 3 months;
   c. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

*Prescribed regimen must be FDA-approved or recommended by NCCN

Approval duration: 12 months

F. Gender Dysphoria (off-label) (must meet all):
1. Diagnosis of gender dysphoria:
2. Prescribed by or in consultation with an endocrinologist and an expert in gender dysphoria and transgender medicine (e.g., mental health professional such as psychologist, psychiatrist);
3. Age and pubertal development - meets (a or b):
   a. Member has reached or passed through Tanner Stage 2* and is < 18 years of age;
   b. Member is ≥ 18 years of age and has failed to achieve physiologic hormone levels with gender-affirming hormonal therapy (e.g., estrogen, testosterone) unless contraindicated or clinically significant adverse effects are experienced;
4. Member demonstrates understanding of expected GnRH analogue treatment outcomes and has given consent for such treatment;
5. If member has a psychiatric comorbidity, member is followed by mental health provider;
6. Psychosocial support will be provided during treatment;
7. Request is not for Lupaneta Pack;
8. Dose is within FDA maximum limit for any FDA-approved indication or is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

Approval duration: 12 months

G. Other diagnoses/indications
1. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).
II. Continued Therapy
   A. Prostate Cancer (must meet all):
      1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions, or documentation supports that member is currently receiving leuprolide acetate or Eligard/Lupron Depot for prostate cancer and has received this medication for at least 30 days;
      2. Request is for leuprolide acetate injection or Eligard/Lupron Depot (7.5 mg, 22.5 mg, 30 mg, 45 mg);
      3. Member is responding positively to therapy;
      4. If request is for a dose increase, request meets any of the following (a, b, or c):
         a. Leuprolide acetate injection (SC): New dose does not exceed 1 mg per day;
         b. Eligard (SC)/Lupron Depot (IM): New dose does not exceed 7.5 mg per month, 22.5 mg per 3 months, 30 mg per 4 months, or 45 mg per 6 months;
         c. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).
   B. Endometriosis (must meet all):
      1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions or member has previously met initial approval criteria;
      2. Request is for Lupron Depot/Lupaneta Pack (3.75 mg, 11.25 mg);
      3. Member is responding positively to therapy as evidenced by, including but not limited to, improvement in any of the following parameters: improvement in dysmenorrhea, dyspareunia, pelvic pain/induration/tenderness, size of endometrial lesions;
      4. If request is for a dose increase, new dose does not exceed 3.75 mg per month or 11.25 mg per 3 months.
   C. Uterine Fibroids (must meet all):
      1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions or member has previously met initial approval criteria;
      2. Request is for Lupron Depot (3.75 mg, 11.25 mg);
      3. Member is responding positively to therapy;
      4. If request is for a dose increase, new dose does not exceed 3.75 mg per month or 11.25 mg per 3 months.
   D. Central Precocious Puberty (must meet all):
      1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions or member has previously met initial approval criteria;
      2. Request is for leuprolide acetate or Lupron Depot-Ped;
      3. Member is responding positively to therapy as evidenced by, including but not limited to, improvement in any of the following parameters: decreased growth velocity, cessation of menses, softening of breast tissue or testes, arrested pubertal progression;
      4. Member meets one of the following age requirements (a or b):
         a. Female: ≤ 11 years;
         b. Male: ≤ 12 years;
      5. If request is for a dose increase, new dose does not exceed one of the following (a or b):
         a. Leuprolide acetate (SC): Initial: 50 mcg/kg per day; titrate dose upward by 10 mcg/kg per day if down-regulation is not achieved (higher mg/kg doses may be required in younger
E. Breast and Ovarian Cancer (off-label) (must meet all):
1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions, or documentation supports that member is currently receiving Lupron Depot for breast or ovarian cancer and has received this medication for at least 30 days;
2. Request is for one of the following (a or b):
   a. Breast cancer: Lupron Depot 3.75 mg;
   b. Ovarian cancer: Lupron Depot 3.75 mg or 11.25 mg;
3. Member is responding positively to therapy;
4. If request is for a dose increase, request meets one of the following (a, b, or c):*
   a. Breast or ovarian cancer: New dose does not exceed 3.75 mg per month;
   b. Ovarian cancer: New dose does not exceed 11.25 mg per 3 months;
   c. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

*Prescribed regimen must be FDA-approved or recommended by NCCN

Approval duration: 12 months

F. Gender Dysphoria (off-label) (must meet all):
1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions or member has previously met initial approval criteria;
2. Member is responding positively to therapy;
3. If request is for a dose increase, new dose is within FDA maximum limit for any FDA-approved indication or is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

Approval duration: 12 months

G. Other diagnoses/indications (must meet 1 or 2):
1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions and documentation supports positive response to therapy.

   Approval duration: Duration of request or 6 months (whichever is less); or
2. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

III. Diagnoses/Indications for which coverage is NOT authorized:
A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off-label use policy – ERX.PA.01 or evidence of coverage documents.

IV. Appendices/General Information
Appendix A: Abbreviation/Acronym Key
- CPP: central precocious puberty
- DSM-5: Diagnostic and Statistical Manual of Mental Disorders, 5th edition
- FDA: Food and Drug Administration
- GnRH: gonadotropin-releasing hormone
- LH: luteinizing hormone
- NCCN: National Comprehensive Cancer Network
Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent and may require prior authorization.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Dose Limit/ Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>NSAIDs*: ibuprofen, naproxen, fenoprofen, ketoprofen, mefenamic acid, meclofenamate, indomethacin, tolmetin, diclofenac, etodolac, diflunisal, meloxicam, piroxicam</td>
<td>Endometriosis</td>
<td>Varies – refer to specific prescribing information</td>
</tr>
<tr>
<td>Combined oral estrogen-progesterone contraceptives*: ethinyl estradiol + (desogestrel, ethynodiol diacetate, drospirenone, etonogestrel, levonorgestrel, norelgestromin, norethindrone, norgestimate, or norgestrel); estradiol valerate + dienogest; mestranol + norethindrone</td>
<td>Endometriosis</td>
<td>1 tablet PO QD (may vary per specific prescribing information)</td>
</tr>
<tr>
<td>Progestin-only oral contraceptives*: norethindrone</td>
<td>Endometriosis</td>
<td>0.35 mg per day</td>
</tr>
<tr>
<td>Depot progestin contraceptives*: medroxyprogesterone acetate</td>
<td>Endometriosis</td>
<td>See regimen</td>
</tr>
</tbody>
</table>

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic. *Examples provided may not be all-inclusive

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s):
  - Known hypersensitivity to GnRH, GnRH agonist analogs or any of the components of the individual products (all leuprolide products);
  - Pregnancy (all leuprolide products except Eligard);
  - Lupron 3.75 mg/11.25 mg and Lupaneta Pack:
    - Undiagnosed abnormal vaginal bleeding
    - Breast-feeding
    - If used with norethindrone acetate
      - Thrombophlebitis, thromboembolic disorders, cerebral apoplexy, or a past history of these conditions;
      - Markedly impaired liver function or liver disease;
      - Known or suspected carcinoma of the breast.
- Boxed warning(s): none reported
# CLINICAL POLICY

## Leuprolide Acetate

### V. Dosage and Administration

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leuprolide acetate injection</td>
<td>Prostate cancer</td>
<td>1 mg SC QD</td>
<td>See regimen</td>
</tr>
<tr>
<td>Leuprolide acetate (Lupron Depot 7.5, 22.5, 30, 45)</td>
<td>Prostate cancer</td>
<td>IM - 7.5 mg per month; 22.5 mg per 3 months; 30 mg per 4 months; 45 mg per 6 months</td>
<td>See regimen</td>
</tr>
<tr>
<td>Leuprolide acetate (Eligard 7.5, 22.5, 30, 45)</td>
<td>Prostate cancer</td>
<td>SC - 7.5 mg per month; 22.5 mg per 3 months; 30 mg per 4 months; 45 mg per 6 months</td>
<td>See regimen</td>
</tr>
<tr>
<td>Leuprolide acetate (Lupron Depot 3.75, 11.25)</td>
<td>Endometriosis</td>
<td>IM: 3.75 mg per month; 11.25 mg per 3 months</td>
<td>See regimen</td>
</tr>
<tr>
<td>Leuprolide acetate (Lupron Depot 3.75)</td>
<td>Uterine fibroids</td>
<td>IM: 3.75 mg per month, 11.25 mg per 3 months</td>
<td>See regimen</td>
</tr>
<tr>
<td>Leuprolide acetate injection</td>
<td>CPP</td>
<td>SC:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Diagnostic: 20 mcg/kg or as needed;</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Treatment: Initial: 50 mcg/kg/day;</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>titrate dose upward by 10 mcg/kg/day if down-regulation is</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>not achieved (higher mg/kg doses may be required in younger</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>children).</td>
<td></td>
</tr>
<tr>
<td>Leuprolide acetate (Lupron Depot-Ped 7.5, 11.25, 15 [1 mo]; 11.25, 30 [3 mol])</td>
<td>CPP</td>
<td>IM monthly: weight-based starting dose: 7.5 mg (&lt; 25 kg), 11.25 mg (&gt; 25 to 37.5 kg), 15 mg (&gt; 37.5 kg) (increase as needed to 15 mg per month); 3-month administration: 11.25 mg or 30 mg</td>
<td>See regimen</td>
</tr>
<tr>
<td>Leuprolide acetate (Lupron Depot 3.75)</td>
<td>Breast cancer</td>
<td>3.75 mg IM per month</td>
<td>See regimen</td>
</tr>
<tr>
<td>Leuprolide acetate (Lupron Depot 3.75, 11.25)</td>
<td>Ovarian cancer</td>
<td>3.75 mg IM per month, 11.25 mg IM per 3 months</td>
<td>See regimen</td>
</tr>
</tbody>
</table>

### VI. Product Availability

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leuprolide acetate injection (generic)</td>
<td>Kit: 2.8 mL multi-dose vial (1 mg/0.2 mL)</td>
</tr>
<tr>
<td>Leuprolide acetate (Eligard 7.5, 22.5, 30, 45)</td>
<td>Kit: 7.5 mg (1 month), 22.5 mg (3 month), 30 mg (4 month), 45 mg (6 month)</td>
</tr>
<tr>
<td>Leuprolide acetate (Lupron Depot 7.5, 22.5, 30, 45)</td>
<td>Prefilled syringe: 7.5 mg (1 month), 22.5 mg (3 month), 30 mg (4 month), 45 mg (6 month)</td>
</tr>
</tbody>
</table>
### Drug Name | Availability
--- | ---
Leuprolide acetate and norethindrone acetate tablets (Lupaneta Pack 3.75, 11.25) | Pack: 3.75 mg leuprolide acetate syringe (1 month) with 5 mg norethindrone tablets  
Pack: 11.25 mg leuprolide acetate syringe (3 month) with 5 mg norethindrone tablets
Leuprolide acetate (Lupron Depot 3.75) | Prefilled syringe: 3.75 mg (1 month)
Leuprolide acetate (Lupron Depot 11.25) | Prefilled syringe: 11.25 mg (3 month)
Leuprolide acetate (Lupron Depot-Ped 7.5, 11.25) | Prefilled syringe: 7.5 mg (1 month), 11.25 mg (1 month), 15 mg (1 month)  
Prefilled syringe: 11.25 mg (3 month), 30 mg (3 month)
Leuprolide acetate injection (generic) | 1 mg/0.2 mL
Leuprolide acetate (Eligard 7.5, 22.5, 30, 45) | Kit: 7.5 mg (1 month), 22.5 mg (3 month), 30 mg (4 month), 45 mg (6 month)
Leuprolide acetate (Lupron Depot 7.5, 22.5, 30, 45) | Prefilled syringe: 7.5 mg (1 month), 22.5 mg (3 month), 30 mg (4 month), 45 mg (6 month)
Leuprolide acetate and norethindrone acetate tablets (Lupaneta Pack 3.75, 11.25) | Pack: 3.75 mg leuprolide acetate syringe (1 month) with 5 mg norethindrone tablets  
Pack: 11.25 mg leuprolide acetate syringe (3 month) with 5 mg norethindrone tablets
Leuprolide acetate (Lupron Depot 3.75) | Prefilled syringe: 3.75 mg (1 month)

### VII. References

Gender Dysphoria


<table>
<thead>
<tr>
<th>Reviews, Revisions, and Approvals</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy created</td>
<td>05.16</td>
<td>09.16</td>
</tr>
<tr>
<td>Converted to new template.</td>
<td>07.17</td>
<td>08.17</td>
</tr>
<tr>
<td>All indications: Specified which formulations can be requested for each indication. Added pregnancy CI. Added preferencing criteria per formulary. For re-auth, added requirement for positive response to therapy. CPP: Added lower age limit of 2 years per PI (should not be used in those &lt; 2 years). Endometriosis/pelvic pain: Modified trial requirement to require both NSAIDs and oral contraceptives. Prostate cancer: NCCN recommended uses added. Doses removed. Off-label uses are referred to the off-label use policy.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4Q17 Annual Review</td>
<td>09.17</td>
<td>11.17</td>
</tr>
<tr>
<td>Dosing added to oncology criteria. Positive therapeutic response examples added to oncology and endometriosis criteria. Oncology FDA/NCCN (categories 1 and 2A) indications listed separately.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th>Pelvic pain criteria deleted with direction to suspected endometriosis if appropriate. Endometriosis step therapy edited from estrogen/progestin OC to OC or depot contraceptive or progestin. Total approval duration increased from 6 to 12 months. Concomitant iron therapy and specific time period within which surgery must be performed are removed from fibroid criteria. Total approval duration increased from 3 to 6 months. Specialist requirement added for endometriosis, fibroids, CPP. Preferencing removed for CPP.</th>
<th>08.07.18</th>
</tr>
</thead>
<tbody>
<tr>
<td>4Q 2018 annual review: no significant changes; for oncology, summarized NCCN and FDA-approved uses for improved clarity (limited to diagnosis) and added specialist involvement in care; references reviewed and updated.</td>
<td>11.18</td>
</tr>
<tr>
<td>Addition of gender dysphoria as off-label use.</td>
<td>07.16.19</td>
</tr>
<tr>
<td>4Q 2019 annual review: Prostate cancer – removed Eligard redirection as it is on the formulary with similar placement to alternatives, added urologist specialist option; references reviewed and updated.</td>
<td>08.01.19</td>
</tr>
</tbody>
</table>

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information.

This Clinical Policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members.

This policy is the property of Envolve Pharmacy Solutions. Unauthorized copying, use, and distribution of this Policy or any information contained herein is strictly prohibited. By accessing this policy, you agree to be bound by the foregoing terms and conditions, in addition to the Site Use Agreement for Health Plans associated with Envolve Pharmacy Solutions.

©2016 Envolve Pharmacy Solutions. All rights reserved. All materials are exclusively owned by Envolve Pharmacy Solutions and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Envolve Pharmacy Solutions. You may not alter or remove any trademark, copyright or other notice contained herein.